Audit of 1 year survival for patients receiving chemotherapy for NSCLC - all comers

被引：0
|
作者：
Allison, J. L. E. [1 ]
Lord, H. [2 ]
机构：
[1] NHS Tayside, Med Oncol, Dundee, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, NHS Tayside, Oncol, Dundee DD1 9SY, Scotland
来源：
LUNG CANCER | 2016年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [21] Exposure to Antibiotics May Affect Progression-Free Survival Negatively in NSCLC Patients Receiving First-Line Chemotherapy
    Tian, X.
    Gong, Y.
    Mei, T.
    Yang, X.
    Xu, Y.
    Yu, M.
    Li, Y.
    Zhu, J.
    Huang, M.
    Zhang, Y.
    Peng, F.
    Zhou, L.
    Zhou, X.
    Xue, J.
    Liu, Y.
    Zou, B.
    Wang, Y.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S397 - S398
  • [22] COMPARE II-1 Year Outcomes of a large randomized all-comers study
    Smits, Peter
    van Boven, A. J.
    Valdes, Mariano
    Serra, Antonio
    Goy, Jean-Jacques
    Voudris, V.
    Vazquez, J. M.
    Trillo, Ramiro
    Vuillomenet, A. G.
    Slagboom, Ton
    den Heijer, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : B168 - B168
  • [23] A retrospective audit into the prophylactic use of antibiotics in patients receiving chemotherapy for lung cancer
    Crockett, Cathryn
    Nillegoda, Hasanthi
    Ooi, Kai Yun
    Harris, Margaret
    LUNG CANCER, 2021, 156 : S34 - S34
  • [24] DELAY IN CHEMOTHERAPY TREATMENT AND ITS RELATIONSHIP WITH SURVIVAL IN PATIENTS WITH ADVANCED NSCLC
    Richardet, Eduardo A.
    Castagneris, Nicolas
    Richardet, Martin
    Perelli, Laura
    Molina, Matias
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S127 - S128
  • [25] Serum Proteomic Signature as a Potential Biomarker for Survival in Patients with NSCLC Receiving Immunotherapy
    Kim, W. B.
    Viveiros, P.
    Anker, J.
    Simon, N.
    Rhee, K.
    Song, J.
    Cho, A.
    Chang, S.
    Ko, T.
    Oh, M.
    Davis, A.
    Park, L. C.
    Chae, Y. K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S793 - S794
  • [26] Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy
    Ina, Kenji
    Furuta, Ryuichi
    Kataoka, Takae
    Kayukawa, Satoshi
    Yoshida, Takashi
    Miwa, Takaya
    Yamamura, Yoshitaka
    Takeuchi, Yuuki
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2011, 2 (10): : 339 - 343
  • [27] ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
    Zou, Wei
    Yaung, Stephanie J.
    Fuhlbrueck, Frederike
    Ballinger, Marcus
    Peters, Eric
    Palma, John F.
    Shames, David S.
    Gandara, David
    Jiang, Yuqiu
    Patil, Namrata S.
    JCO PRECISION ONCOLOGY, 2021, 5 : 827 - 838
  • [28] Blood transfusion requirements of NSCLC patients receiving chemotherapy in the BTOG2 trial
    Best, J.
    Young, R.
    Ddamba, J.
    Danson, S. J.
    Fisher, P. M.
    Foran, B.
    Hatton, M.
    Lee, C.
    Mohanamurali, J.
    Woll, P. J.
    LUNG CANCER, 2013, 79 : S15 - S16
  • [29] Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)
    Bischoff, Helge G.
    van den Borne, Ben
    Pimentel, Francisco L.
    Arellano, Jorge
    Langer, Frank
    Leschinger, Monika I.
    Thatcher, Nicholas
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1461 - 1470
  • [30] 1-Year Clinical Performance of COMBO Stent Versus Xience Stent in All-Comers Patients With Coronary Artery Disease
    Kalkman, Deborah N.
    Tijssen, Ruben Y. G.
    Kraak, Robin P.
    Woudstra, Pier
    Beijk, Marcel A.
    Tijssen, Jan G. P.
    Piek, Jan J.
    Henriques, Jose P. S.
    de Winter, Robbert J.
    Wykrzykowska, Joanna J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (01) : 102 - 103
12345